Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Sacubitril/Valsartan vs Entresto in Healthy Volunteers
NCT06248112Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of sacubitril + valsartan in heart failure (HF) (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 48 hours, Maximal measured plasma concentration at 48 hours and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06248112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248112.